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Abstract
Background: Tumor-infiltrating lymphocytes (TILs) evaluated in primary breast cancer (BC) convey prognostic
information. Limited data in the metastatic setting are available.
Methods: Secondary lesions from 94 BC patients, 43 triple-negative (TN) and 51 HER2-positive, were evaluated for
TILs and expression of CD8, FOXP3, and PD-L1 by immunohistochemistry.
Results: TILs levels on metastasis were generally low (median 5%) and did not differ between TN and HER2+ tumors.
Younger patients showed significantly lower TILs (p = 0.002). In HER2+ patients, TILs were higher in lung metastases as
compared to other sites (p = 0.038). TILs composition was different across metastatic sites: skin metastases presented
higher FOXP3 (p = 0.002) and lower CD8/FOXP3 ratio (p = 0.032). Patients treated for metastatic BC prior to biopsy had
lower CD8 (overall: p = 0.005, HER2+: p = 0.011, TN: p = 0.075).
In TN patients, median overall survival (OS) was 11.8 and 62.9 months for patients with low and high TILs, respectively
(HR 0.29, 95%CI 0.11–0.76, log-rank p = 0.008). CD8/FOXP3 ratio was also prognostic in TN patients (median OS 8.0, 13.2,
and 54.0 months in 1st, 2nd and 3th tertile, log-rank p = 0.019). Both TILs and CD8/FOXP3 ratio were independent
factors at multivariate analysis. Counterintuitively, in HER2+ BC, low TILs tumors showed better prognosis (median OS
53.7 vs 39.9 months in TILs low and TILs high, not statistically significant).
Conclusions: Our findings indicate the relevance of TILs as prognostic biomarker for TNBC even in the advanced
setting and provide novel hypothesis-generating data on potential sources of immune heterogeneity of metastatic BC.
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Background
Tumor-infiltrating lymphocytes (TILs) are believed to reflect
the immunogenicity of breast cancer (BC), with rapidly accu-
mulating evidence suggesting the clinical validity and poten-
tial utility of TILs as a biomarker [1]. Most of available data
focus on early BC, where TILs have proved to retain a strong
prognostic value especially in triple-negative (TN) and hu-
man epidermal growth factor receptor-2 (HER2) positive BC,
when assessed on hematoxylin and eosin-stained (HES) sec-
tions of primary tumor in accordance with International
Immuno-Oncology Biomarker Working Group recommen-
dations [2–9]. In addition, an association between TILs and
response to preoperative chemotherapy (plus anti-HER2
agents if HER2-positive) has been reported [10–15].
In contrast to the early setting, little is known on the
prognostic role of TILs in advanced disease for patients
treated with standard therapies currently available. In
this context, prospective-retrospective data come from
translational analyses of two trials evaluating combina-
tions of chemotherapy and anti-HER2 agents as
first-line for HER2-positive metastatic breast cancer pa-
tients [16, 17]. In the Cleopatra trial (trastuzumab+do-
cetaxel vs pertuzumab+trastuzumab+docetaxel), longer
OS was observed in patients with high TILs levels [16],
whereas in the MA.31 trial (trastuzumab+taxane vs
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lapatinib+taxane) poorer prognosis was observed in
case of low CD8-positive TILs on tumor samples from
patients treated in the lapatinib arm relative to those
receiving trastuzumab [17]. However, as a main limita-
tion of these studies, TILs were assessed almost exclu-
sively on primary tumor samples. Thus, it remains
largely unexplored whether the evaluation of TILs in
secondary lesions could provide more accurate infor-
mation on the actual immunological balance between
tumor and host. Indeed, available evidence suggests
that immune microenvironment may differ between
primary tumor and its paired secondary lesions in
terms of both TILs levels and composition [18–21].
In the present study we aim to assess TILs levels, im-
mune infiltrate composition and programmed death-ligand
1 (PD-L1) expression in metastatic lesions and to evaluate
their prognostic impact for patients with TN and HER2+
advanced BC.
Methods
Study population
We retrospectively included 94 patients with HER2+ or
TN (HR-/HER2-) metastatic BC diagnosed before 2015
at IRCCS Istituto Oncologico Veneto in Padua and
Modena University Hospital for whom histologic mater-
ial obtained with surgical resection or biopsy of regional
or distant recurrence was available (lymphoid tissue me-
tastasis were excluded).
Patients were identified from a prospectively main-
tained institutional database, in which clinicopathologi-
cal characteristics (including histological type, tumor
grade, hormonal receptor, HER2 status and clinical stage
at diagnosis), time and site of recurrence and follow-up
data were recorded.
Patients with ipsilateral in-breast recurrences were ex-
cluded given the difficulty in discriminating between a
recurrence and a new primary lesion.
The study protocol was approved by local ethics
committee.
Pathology assessments
Formalin-fixed paraffin-embedded tumor samples from
metastatic sites and, when available, matched primary
tumor samples were retrieved.
Estrogen receptor (ER) and progesterone receptor
(PgR) were considered positive if immunohistochemistry
(IHC) staining is positive in ≥10% of tumor cells. HER2
was considered negative if it was present in IHC staining
of 0/1+ and/or FISH non-amplified.
TILs evaluation
Hematoxylin and eosin-stained (HES) slides were re-
trieved from Institutional Pathology archives. Stromal
TILs were assessed according to consensus guidelines
[3, 22] by two independent investigators (MVD and
FM), blinded for clinical data. The average value was
used for analyses.
Immunohistochemistry
CD8 and FOXP3 IHC staining was performed by using
the fully automated stainer BOND III (Leica, Wetzler,
Germany). Paraffin slides were deparaffinized in xylene
and rehydrated through graded alcohols. Antigen
retrieval was performed with slides heated in EDTA buf-
fer (pH 9.0) for 20 min at 100 °C.
After antigen retrieval, the slides were allowed to cool.
The slides were rinsed with Tris-buffered saline (TBS) and
the endogenous peroxidase was inactivated with 3%
hydrogen peroxide block at room temperature. After pro-
tein block, the slides were incubated with primary anti-
body to human CD8 (Monoclonal Mouse Anti-Human
CD8, Clone C8/144B, dilution 1:100, Dako Cytomation,
Glostrup, Denmark) and FOXP3 (Monoclonal Mouse
Anti-Human FOXP3, Clone 236A/E7, dilution 1:200,
Abcam, Cambridge, MA, USA) for 15 min. The sections
were rinsed in TBS and incubated for 8 min with the
Post-Primary Antibody (Leica Biosystems). Then, the sec-
tions were rinsed in TBS and incubated for 8 min with
Polymer (Leica Biosystems). Finally, peroxidase reactivity
was visualized using a Mixed DAB Refine, then the sec-
tions were counterstained with hematoxylin for 15 min
and mounted.
PD-L1 IHC staining was performed by using the Ven-
tana automated immunostainer BenchMark ULTRA.
(Ventana Medical Systems, Tucson, AZ, USA). The slides
were dried at 60 °C for 1 h and deparaffinized using EZ
Prep (Ventana Medical Systems) at 72 °C. Cell condition-
ing was performed using ULTRA CC1 solution (Ventana
Medical Systems) at 100 °C for 64 min. Ventana PD-L1
Primary Antibody (rabbit monoclonal, clone SP263 ref.
790–4905, Ventana Medical Systems) was incubated at
36 °C for 16 min. Signals were detected using the Opti-
View DAB IHC Detection Kit (Ventana Medical Systems).
Counterstaining was performed with Hematoxylin II and
Bluing reagent (Ventana Medical Systems).
CD8, FOXP3 and PD-L1 scoring
Evaluation of CD8, FOXP3 and PD-L1 expression was
performed by a pathologist, blinded for clinical data.
For CD8 and FOXP3, five fields of 2–3 mm of diam-
eter were analyzed at ×40 for each sample. The five field
were selected within the area identified for the evalu-
ation of TILs according to available recommendations
[3, 22] and were in the area exhibiting tumor invasion.
The number of positive immune cells in the five selected
fields was counted on a light microscope. For each sam-
ple, the average number of stained immune cells across
the evaluated fields was calculated.
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PD-L1 expression was assessed on the entire section.
PD-L1 was evaluated on tumor cells (% of cells positively
stained/total tumor cells) and on stromal/immune cells
in tumor stroma (% of cells positively stained/total cells
in tumor stroma).
PD-L1 expression was found to be predominant in stro-
mal/immune cells rather than tumor cells, mean expres-
sion on tumor cells was 7%, mean expression on stromal/
immune cells was 15%, t test p = 0.003. Expression in the
two cells compartments was strongly and positively corre-
lated (Spearman’s coefficient 0.554, p < 0.001). Therefore,
we decided to consider stromal/immune cells expression
for further analyses in this study.
Statistical analysis
Statistical analysis was carried out using IBM SPSS
(version 24) software (IBM Corp, Armonk, NY, USA).
Descriptive statistics were performed for patient demo-
graphics and clinical characteristics. For continuous vari-
ables median, range values and quartiles were computed.
The Mann-Whitney nonparametric test was used to study
the distribution of continuous variables across groups
defined by clinicopathologic characteristics.
The Spearman’s rank correlation coefficient was used
to study the correlation between continuous variables.
Overall survival (OS) was defined as the time from
first relapse to death from any cause. Alive patients were
censored at the date of last follow-up. Median OS was
estimated using the Kaplan–Meier method and reported
with 95% confidence intervals (95% CIs). The Kaplan–
Meier method was used to estimate survival curves, the
log-rank test was used to compare between groups. Uni-
variate and multivariate Cox regression modeling for
proportional hazards was used to calculate HR and 95%
CI. All reported p values are two-sided, and significance
level was set at p < 0.05.
The association between TILs levels as continuous
variable and OS was tested. The prognostic value of
TILs levels categorized using a 10% cutoff [16, 20, 23]
was also evaluated. The prognostic value of CD8/FOXP3
ratio was tested using tertiles.
We tested two distinct cutoffs for PD-L1 expression in
stromal/immune cells (1% and 5%) and its association
with OS.
Results
Clinicopathologic characteristics and association with TILs
levels
In the present study, tumor samples of BC recurrences
obtained from 94 patients were assessed (n = 43 TN and
n = 51 HER2+) for TILs.
Patients’ baseline characteristics are reported in
Table 1. Median time from relapse to sample collection
was 0 months, the majority of patients (n = 70, 74%)
underwent biopsy of recurrent BC before starting any
systemic treatment for advanced disease. Most of the pa-
tients received prior neoadjuvant systemic treatment
(86% of patients received chemotherapy, 59% of HER2+
patients received trastuzumab). The majority of tumor
samples were obtained from distant relapses (57%).
Median TIL levels in the overall population was 5%
(Q1 2%; Q3 10%), with similar results in TN and HER2+
patients (median 5%, Q1 2.25% to Q3 10% for TN and
median 5%, Q1 2% to Q3 11% for HER2+; p = 0.885), as
shown in Table 2.
Although TILs were not significantly different across
biopsy sites, lung samples showed the highest levels
among all sites. The comparison of TILs in lung versus
other metastatic sites (all together) was of borderline sig-
nificance in the overall cohort (p = 0.084) and reached
statistical significance in the HER2+ cohort (p = 0.038).
In the entire cohort, skin samples showed the lowest
median TILs levels among all metastatic sites (3.5%),
with similar results in the TN and HER2+ cohorts separ-
ately. However, when comparing skin versus other meta-
static sites altogether, results were not statistically
significant (p = 0.312 in the entire cohort, p = 0.418 in
the TN cohort and p = 0.548 in the HER2+ cohort).
Women who were younger at the time of BC diagnosis
(≤50 years) showed significantly lower TILs on metasta-
sis than older patients (> 50 years) both in the overall
population (p = 0.002) and when each tumor subtype
was considered separately (p = 0.037 and p = 0.010 and
for TN and HER2+ patients, respectively).
In the HER2+ population, TILs were significantly
lower in case of HR+ disease (p = 0.029).
In the TN cohort, there was a nonsignificant trend
for lower TILs for patients who received chemother-
apy for metastatic disease prior to metastasis biopsy,
as compared to patients undergoing biopsy before
starting first-line treatment (median 2%, Q1 2% to Q3
5%; median 5%, Q1 23% to Q3 10%, respectively;
p = 0.104).
Matched primary tumors were available for only 55
patients. TILs were not significantly different in primary
versus matched metastasis (median 5%, Q1 2.5% to Q3
12.5% and median 6.25, Q1 2% to Q3 12.5%, p = 0.925).
In the TN cohort (n = 27), TILs tended to decrease in
metastasis, although not significantly (median 7.5%, Q1
2.5% to Q3 20% in primary and median 6.25, Q1 2% to
Q3 11% in metastasis, p = 0.477). In HER2+ patients
TILs were nonsignificantly higher in metastases (median
2.5%, Q1 2% to Q3 7% in primary and median 6%, Q1
2% to Q3 14% in metastasis, p = 0.452).
TILs composition
CD8 and FOXP3 were assessed on 64 biopsies (n = 36
HER2+, n = 28 TN), while PD-L1 expression was
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available for 62 cases (n = 35 HER2+, n = 27 TN).
Patients’ baseline characteristics are reported in Table 1.
Figure 1 shows a heatmap with Spearman’s coefficients
and p values for the correlation between immune
markers. In the entire cohort, CD8, FOXP3, PD-L1, and
TILs showed a significant positive correlation with each
other. The Spearman’s coefficients showed generally a
moderate correlation between the variables, with the
exception of weak correlations between TILs and
FOXP3, PD-L1 and CD8, and PD-L1 and FOXP3.
Table 1 Patients’ baseline characteristics: overall and according to tumor subtype
Population evaluated for TILs levels Population evaluated for CD8, FOXP3, PD-L1
Overall
n (%)
TN
n (%)
HER2+
n (%)
Overall
n (%)
TN
n (%)
HER2+
n (%)
Tot, n 94 43 51 64 28 36
Age at BC diagnosis, yrs. median (Q1–Q3) 49 (42–57) 51 (44–61) 46 (39–53) 51 (43–59) 54 (45–63) 47 (41–57)
Time to relapse, mos median (Q1–Q3) 27 (15–43) 19 (11–38) 31 (19–60) 27 (16–47) 18 (11–34) 31 (21–55)
Time from relapse to biopsy, mos median (Q1–Q3) 0 (0–5) 0 (0–2) 0 (0–11) 0 (0–6) 0 (0–2) 0 (0–15)
Histotype
Ductal 81 (86) 36 (84) 43 (84) 56 (88) 22 (79) 34 (94)
Lobular 5 (5) 1 (2) 4 (8) 2 (3) 1 (4) 1 (3)
Other 8 (9) 6 (14) 2 (4) 6 (9) 5 (17) 1 (3)
Grade
1–2 13 (14) 3 (7) 10 (20) 9 (14) 2 (7) 7 (19)
3 78 (86%) 39 (93) 39 (80) 54 (86) 25 (83) 29 (81)
HR status
HR+ 37 (39) 0 (0) 37 (72) 26 (41) 0 (0) 26 (72)
HR- 57 (61%) 43 (100) 14 (28) 38 (59) 28 (100) 10 (28)
Stage at diagnosis
I–II 50 (55) 27 (66 23 (46) 33 (52) 17 (63) 16 (44)
III 38 (42) 13 (32) 25 (50) 27 (43) 9 (33) 18 (50)
IV 3 (3) 1 (2) 2 (4) 3 (5) 1 (4) 2 (6)
Type of recurrent BC sample
Locoregional relapse 40 (43) 23 (53) 17 (33) 25 (39) 13 (46) 12 (33)
Distant relapse 54 (57) 20 (47) 34 (67) 39 (61) 15 (54) 24 (67)
Organ/site of biopsy
Liver 24 (25) 5 (12) 19 (37) 15 (23) 4 (14) 11 (31)
Skin 38 (40) 21 (49) 17 (33) 26 (41) 13 (47) 13 (36)
Lung 12 (13) 7 (16) 5 (10) 8 (13) 4 (14) 4 (11)
CNS 9 (10) 4 (9) 5 (10) 9 (14) 4 (14) 5 (14)
Other 11 (12) 6 (14) 5 (10) 6 (9) 3 (11) 3 (8)
Neo/adjuvant chemotherapy
No 13 (14) 3 (7) 10 (20) 9 (14) 3 (11) 6 (17)
Yes 81 (86) 40 (93) 41 (80) 55 (86) 25 (89) 30 (83)
Neo/adjuvant trastuzumab
No – – 21 (41) – – 12 (33)
Yes – – 30 (59) – – 24 (67)
Pre-biopsy systemic treatment for MBC
No 70 (74) 36 (88) 34 (67) 46 (72) 25 (89) 21 (58)
Yes 24 (26) 7 (17) 17 (33) 18 (28) 3 (11) 15 (42)
Abbreviations: TILs tumor-infiltrating lymphocytes, TN triple negative, HER2 human epidermal growth factor receptor-2, n number, tot total, BC breast cancer, yrs
years, mos months, Q1 first quartile, Q3 third quartile, HR hormone receptor, CNS central nervous system, MBC metastatic breast cancer
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The highest Spearman’s correlation coefficients be-
tween TILs, CD8, FOXP3, and PD-L1 were observed in
the TN cohort. The correlations were mostly moderate,
with the exception of a strong correlation between TILs
and FOXP3 and a weak correlation between CD8 and
PD-L1.
In the HER2 cohort, correlation coefficients between
TILs, CD8, FOXP3, and PD-L1 were the lowest. Correla-
tions were very weak to weak, with the exception of the
one between CD8 and FOXP3 that showed a Spearman’s
coefficient of 0.440.
CD8/FOXP3 ratio was obviously positively and nega-
tively correlated with CD8 and FOXP3, respectively, and
did not correlate with TILs or PD-L1.
Full data regarding distribution of CD8, FOXP3, CD8/
FOXP3 ratio, and PD-L1 according to tumor subtype
and other clinical variables is detailed in (Additional file 1:
Tables S1; Additional file 2: Table S2; Additional file 3:
Table S3; and Additional file 4: Table S4).
Distribution of these parameters did not vary signifi-
cantly according to tumor subtype.
Levels of FOXP3 were significantly different across
site of biopsy (0.046). In particular, FOXP3 was sig-
nificantly higher in skin metastases as compared to
other metastatic sites considered all together (p = 0.002).
Accordingly, CD8/FOXP3 ratio was the lowest in skin bi-
opsies as compared to other metastatic sites (p = 0.032).
This trend was seen both in the HER2+ and TN subgroup,
though it only reached statistical significance in the HER2
+ subgroup, as shown in Fig. 2.
Patients who underwent biopsy of metastatic lesion
prior to start first-line treatment showed significantly
higher CD8+ infiltrating lymphocytes as compared to
patients who previously received systemic treatment
for advanced disease: p = 0.005 for overall population
and p = 0.011 for HER2+ tumors. The analysis in the
TN cohort (p = 0.075) was limited by the fact that
only three patients underwent metastasis biopsy prior
to first-line therapy. Most of the HER2+ patients who
received systemic therapy for metastatic disease prior
to biopsy received both chemotherapy and anti-HER2
(13/17, 76.5%).
CD8/FOXP3 ratio was higher in HR+/HER2+ as
compared to HR-/HER2+ patients (p = 0.052); how-
ever, this might in part be confounded by the fact
that more HR-/HER2+ patients had skin metastasis
biopsies than HR+/HER2+ patients (43% vs 27%,
p = 0.277).
Table 2 TILs distribution according to tumor subtype and
clinical characteristics
TILs %, median (Q1 – Q3): all patients 5 (2–10)
Overall p value TN p value HER2+ p value
Tumor phenotype
TN 5 (2–10) – –
HER2+ 5 (2–11) 0.855 – – – –
Age at BC diagnosis
≤ 50 years 3 (2–8) 0.002 3 (2–10) 0.037 4 (2–8) 0.010
> 50 years 8 (5–15) 7 (4–11) 9 (5–18)
HR status
Negative – – – – 9 (5–15) 0.029
Positive – – 4 (2–8)
Organ/site of biopsy
Liver 5 (2–8) 0.277 5 (5–11) 0.936 5 (2–8) 0.119
Skin 3(2–10) 3 (2–10) 4 (2–10)
Lung 9 (5–18) 8 (3–10) 18 (6–19)
CNS 6 (3–11) 4 (3–38) 11 (5–11)
Other 5 (2–8) 5 (2–19) 5 (2–8)
Pre-biopsy systemic treatment for MBC
No 5 (3–11) 0.563 5 (3–10) 0.104 4 (2–13) 0.652
Yes 5 (2–8) 2 (2–5) 6 (5–9)
Abbreviations: TILs tumor-infiltrating lymphocytes, Q1 first quartile, Q3 third
quartile, p p value, significant values in bold, TN triple negative, HER2 human
epidermal growth factor receptor-2, BC breast cancer, HR hormone receptor,
CNS central nervous system, MBC metastatic breast cancer
a
b
c
Fig. 1 Correlations between immune parameters. Heatmap showing
Spearman’s coefficients and statistical significance (p values) for the
correlation between immune markers in the overall population (a), TN
cohort (b) and HER2+ cohort (c). Significant p values in bold. PD-L1
programmed death-ligand 1, TILs tumor-infiltrating lymphocytes
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Impact on survival
Due to profound differences in disease course and thera-
peutic options, the prognostic value of immune bio-
markers was assessed separately in the TN and HER2+
cohorts.
In the TN population, TILs had a significant prognos-
tic impact on OS (median OS 11.8 months vs
62.9 months for TILs low and TILs high, respectively;
HR 0.29, 95% CI 0.11–0.76, p = 0.012) (Fig. 3a). Each 1%
increase in TILs was associated with a 3% reduction in
the risk of death (HR 0.97, 95% CI 0.94–1.00, p = 0.075).
Since we did not show significantly different TILs levels
between primary and metastasis in the 27 TN cases with
available samples, we explored, in this subgroup, the
prognostic value of TILs in primary tumor and in metas-
tasis. TILs in metastasis were significantly associated
with OS (HR 0.29, 95% CI 0.09–0.91, p = 0.033), whereas
TILs in primary tumor did not (HR 0.50, 95% CI 0.19–
1.34, p = 0.170). In addition, CD8/FOXP3 ratio on me-
tastasis also showed a prognostic role in TN patients
(median OS 8.0, 13.2 and 54.0 months in the first, sec-
ond and third tertile, respectively; p = 0.019) (Fig. 3b).
TILs and CD8/FOXP3 ratio were weakly correlated
(Fig. 1), indeed, biopsies with high CD8/FOXP3 ratios
(third tertile) were almost exclusively characterized by
low TILs (eight out of nine cases with high CD8/FOXP3
ratio). In a multivariate Cox regression analysis both
TILs and CD8/FOXP3 ratio maintained an independent
prognostic value in TN tumors (Table 3) and the com-
bined use of TILs and CD8/FOXP3 ratio allowed refin-
ing the prognostic ability of single biomarkers (median
OS 8.0 months for tumors with low TILs and low CD8/
a
b
Fig. 2 CD8, FOXP3, and CD8/FOXP3 ratio in skin versus other metastasis sites. Boxplots comparing CD8, FOXP3, and CD8/FOXP3 ratio in skin versus other
metastasis sites in all patients and in TN and HER2+ cohorts separately (a). Pictures showing a skin metastasis with high TILs and low CD8/FOXP3 ratio and
a liver metastasis with low TILs and high CD8/FOXP3 ratio (b). HER2 human epidermal growth factor receptor-2, TILs tumor-infiltrating lymphocytes, TN
triple negative.
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FOXP3 ratio vs 54.0 months for tumors with high TILs
and/or high CD8/FOXP3 ratio, p < 0.001, Fig. 3c).
In the HER2+ population, an inverse relationship be-
tween TILs and prognosis was observed, with patients
with lower TILs showing better prognosis (not statisti-
cally significant): median OS was 53.7 months vs
39.9 months for TILs low and TILs high, respectively;
p = 0.136 (Fig. 3d). Results were similar in HR-/HER2+
and HR+/HER2+ patients, although the analysis was
limited by reduced sample size. In HR-/HER2+, median
OS was 50.3 months vs 15.1 months for patients with
low and high TILs, respectively (HR 2.45, 95%CI 0.54–
a b
c d
Fig. 3 Overall survival (OS) according to immune biomarkers assessed on metastasis. OS in the triple-negative cohort according to TILs (a), CD8/
FOXP3 ratio (b) and CD8/FOXP3 ratio combined with TILs (c); OS in the HER2+ cohort according to TILs levels (d). CI confidence interval, HR hazard
ratio, OS overall survival, TILs tumor-infiltrating lymphocytes
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11.16). In HR+/HER2+ patients median OS was 68.9 and
47.1 months in case of low and high TILs, respectively
(HR 1.54, 95% CI 0.55–4.28). CD8/FOXP3 ratio did not
show any prognostic role (Additional file 5: Figure S1).
PD-L1 expression in tumor stroma was not prognostic
in TN and in HER2+ tumors when considering a 5%
cutoff (Additional file 6: Figure S2). Similar results were
obtained with a 1% cutoff (data not shown).
Discussion
This article reports the assessment of immune-related
biomarkers for patients with TN and HER2+ metastatic
breast cancer. The series of samples analyzed in this
work represents the largest published series of metastatic
breast cancer samples analyzed for immune biomarkers.
In our study, TILs were generally low. It is now recog-
nized that patients with HER2+ and TN early BC with
high levels of TILs on primary tumor have a lower
recurrence rate [2–9], therefore suggesting that BC
recurrences might be enriched in low TILs tumors.
Moreover, previous reports showed lower TIL levels in
secondary lesions as compared to primary tumors
[16, 18, 19]. We only found a nonsignificant decrease in
TILs from primary to metastasis in the TN cohort of
our study, however, the sample size of patients with
matched samples was small.
We observed that host-dependent factors are associ-
ated with TILs on metastasis. In particular, younger
women showed lower levels of TILs than older patients.
This is the first time that such correlation is reported for
patients with metastatic disease. The reason for lower
TILs levels in younger patients is largely unknown. A
potential underexplored hypothesis is that younger pa-
tients present higher levels of circulating estrogens,
which might have an immunosuppressive action
[24, 25]. However, most of the patients had received
neoadjuvant chemotherapy, which might have induced
iatrogenic menopause and, unfortunately, it was not pos-
sible to capture the menopausal status of these patients
at the time of metastatic disease onset. Other
host-related factors such as race have been also shown
to be associated with differing levels of immune infiltrate
in a previous study [16].
We found in our analysis that the characteristics of
the tumor immune infiltrate may be different across
metastatic sites. We observed the highest TILs levels in
lung metastasis and the lowest levels in skin secondary
lesions, which is consistent with previous data [16, 20].
Interestingly, we also could appreciate differences in im-
mune infiltrate composition. In particular, skin metasta-
sis presented significantly higher FOXP3 levels and
lower CD8/FOXP3 ratio, as compared to other biopsy
sites. This may suggest that cutaneous tissue might har-
bor a more permissive immune microenvironment for
tumor growth. A physiological mitigation of the cyto-
toxic immune activity in skin tissue through different
immunosuppressive mechanisms, a process known as
“immune privilege”, has been described by several
authors [26, 27]. The immune heterogeneity across
metastatic sites deserves to be further explored, due to
potential relevance in explaining heterogeneous response
to standard treatments and to immunotherapy.
Another factor that was found to be significantly re-
lated to TILs composition is previous treatment. Having
received CT or anti-HER2 therapy in the metastatic set-
ting prior to biopsy was associated with lower CD8+
TILs. Recently, Loi et al. reported lower levels of TILs
for TN patients treated with multiple lines of chemo-
therapy as compared to patients who did not receive
treatment for metastatic disease [20]. These data suggest
that heavily pretreated patients might have an impaired
antitumor cytotoxic activity of the immune system thus
possibly explaining, at least in part, data from immune
checkpoint inhibitor trials showing better response rates
in first-line treatment than in subsequent lines [28–30].
TILs showed a strong prognostic value in TN BC, fur-
ther corroborating the relevance of TILs as a biomarker
in this disease subtype across different settings. TILs
were significantly correlated with CD8, FOXP3, and
PD-L1 in TN disease in our study, suggesting that the
levels of TILs in TN reflect a general activation of the
immune system. This observation supports TILs as a
Table 3 OS univariate and multivariate analysis of immune parameters evaluated on metastasis biopsies of triple-negative breast
cancer
Univariate Multivariate
Median OS
months (95%CI)
HR (95%CI) p HR (95%CI)
TILs Low ≤10% 11.8 (4.1–19.5) ref 0.012 ref
High > 10% 62.9 (52.3–73.5) 0.29 (0.11–0.76) 0.06 (0.01–0.29)
CD8/FOXP3 ratio 1st tertile 8.0 (0.0–17.1) ref 0.020 ref
2nd tertile 13.2 (0.0–28.3) 0.59 (0.22–1.58) 0.17 (0.05–0.59)
3rd tertile 54.0 (32.4–75.7) 0.20 (0.06–0.67) 0.03 (0.004–0.15)
Abbreviations: OS overall survival, HR hazard ratio, p p value, TILs tumor-infiltrating lymphocytes
Significant p values in bold
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simple method to appreciate the immune activation sta-
tus of a TN tumor. Indeed, given the availability of a
standardized methodology for TILs assessment in the
metastatic setting, the evaluation of this immune marker
is technically simple and clinically reliable [22]. In
addition, CD8/FOXP3 ratio was capable of identifying
an additional subgroup of TN BC patients at good prog-
nosis, which were not captured by the high TILs group.
This hypothesis-generating result highlights that a finer
evaluation of tumor microenvironment may be worthy
of investigation in future studies.
Other well-known immune-related markers, such as
PD-L1 expression, did not significantly affect outcome.
The clinical utility of TILs may not be confined to its
prognostic value; in fact in recent studies of immune
check-point inhibitors for metastatic TN BC patients,
TILs rather than PD-L1 are a better predictor of re-
sponse to immunotherapy [20, 23].
A different scenario was observed in HER2+ BC,
where we did not observe any favorable impact of high
TILs on OS. This result may appear in conflict with data
from Cleopatra study [16], where higher TIL values were
associated with improved OS. However, our HER2+
population was mostly represented by patients previ-
ously treated with anti-HER2 agents (60%) with samples
obtained from metastases, while in the Cleopatra trial
only a small proportion of patients was pretreated with
anti-HER2 therapy (10.9%) and the majority of samples
analyzed came from the primary tumor. As previously
discussed, pretreatment with CT or HER2-targeted ther-
apy may modify tumor immune microenvironment lead-
ing to impaired antitumor cytotoxic activity of the
immune system.
Conclusions
The main results of this study further stress the relevance
of TILs as a prognostic biomarker for TN even in the ad-
vanced setting and provide novel hypothesis-generating
data with regards to immune composition across different
metastatic sites and the influence of previous treatments.
Finally, the more complex interplay between the immune
system and HER2+ BC deserve further exploration in the
metastatic setting.
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